Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has surged over 10% today, with a cumulative increase of nearly 70% this week, driven by positive news regarding patent approvals for its core product CBT-009 [1] Group 1: Stock Performance - As of the latest update, the stock is up 8.82%, trading at 7.9 HKD, with a transaction volume of 6.2189 million HKD [1] - The significant rise in stock price indicates strong market interest and potential investor confidence in the company's future prospects [1] Group 2: Product Development - Bolekang Vision Cloud announced that its wholly-owned subsidiary, ADS USA, has successfully obtained patents from the Japan Patent Office and the European Patent Office for CBT-009 [1] - CBT-009 is a novel atropine eye preparation aimed at treating myopia in children and adolescents aged 5 to 19 [1] - The company anticipates establishing licensing arrangements with major pharmaceutical companies for the production, development, and distribution of CBT-009 in Japan and Europe [1] Group 3: Market Context - A report highlighted that on January 3, 2026, two cornerstone investors of Bolekang Vision Cloud will face a lock-up expiration, which could impact stock liquidity [1] - The stock's performance has been characterized by a lack of institutional funding, leading to insufficient national placement, which may have contributed to initial underperformance in the dark market and on the listing day [1]
港股异动 | 拨康视云-B(02592)再涨超10% 核心产品CBT-009获得日本及欧洲专利